Atrasentan in Patients with IgA Nephropathy
In this prespecified interim analysis, atrasentan resulted in a significant and clinically meaningful reduction in proteinuria as compared with placebo in patients with IgA nephropathy. (Funded by Novartis; ALIGN ClinicalTrials.gov number, NCT04573478.).
Authors
- Hiddo J.L. Heerspink (ORCID: https://orcid.org/0000-0002-3126-3730)
- Adrian Liew (ORCID: https://orcid.org/0000-0002-0963-6270)
- Todd Gray
- Abhay Lodha (ORCID: https://orcid.org/0000-0001-7309-9011)
- Adeera Levin (ORCID: https://orcid.org/0000-0003-2438-8401)
- Jonathan Barratt (ORCID: https://orcid.org/0000-0002-9063-7229)
- Richard Lafayette (ORCID: https://orcid.org/0000-0003-3906-7934)
- Ronny Renfurm
- Donald E. Kohan (ORCID: https://orcid.org/0000-0002-3981-2941)
- Hong Zhang (ORCID: https://orcid.org/0000-0003-4037-7497)
- Meg Jardine (ORCID: https://orcid.org/0000-0002-0160-2375)
- Yi-Xiang Wang (ORCID: https://orcid.org/0000-0002-5246-5497)
Institutions
- Novartis (Switzerland) (CH)
- The University of Sydney (AU)
- University Medical Center Groningen (NL)
- University of British Columbia (CA)
- University of Leicester (GB)
- University of Groningen (NL)
- Peking University (CN)
- University of Utah (US)
- Mount Elizabeth Novena Hospital (SG)
- Novartis (United States) (US)
- Utah Department of Health (US)
- Peking University First Hospital (CN)
- University of Utah Health Care (US)
- Neoleukin Therapeutics (United States) (US)
- National Health and Medical Research Council (AU)
- Stanford University (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1056/nejmoa2409415
- Citations
- 78
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 26.12
Funders
- Novartis